Sign in
CCCC Stock Price, Chart, Stats & News
C4 Therapeutics, Inc.
Save
363.61M
Market cap
–
Current P/E
–
Forward P/E
CCCC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.98% |
Operating margin | -320.53% |
Pretax margin | -291.74% |
Net margin | -292.08% |
Effective tax rate | -0.12% |
ROA | -29.24% |
ROE | -53.83% |
D/E | 0.23x |
Interest coverage ratio | – |
CCCC valuation
P/E | – |
P/S | 5.55x |
P/B | 0.78x |
P/CF | -2.02x |
P/FCF | -2.01x |
P/OCF | -2.02x |
PEG | -0.10x |
EV multiple | -1.98x |
About
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins.
Similar securities
Based on sector and market capitalization
Report issue